Targeting the gastrin-releasing peptide receptor pathway to treat cognitive dysfunction associated with Alzheimer's Disease

Detalhes bibliográficos
Autor(a) principal: Roesler,Rafael
Data de Publicação: 2007
Outros Autores: Luft,Tatiana, Schwartsmann,Gilberto
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Dementia & Neuropsychologia
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1980-57642007000200118
Resumo: Abstract Increasing evidence indicates that bombesin (BB)-like peptides (BLPs), such as the gastrin-releasing peptide (GRP) and its receptor (GRPR), might play a role in neurological and psychiatric disorders. The present study reviews findings from animal and human studies suggesting that the GRPR should be considered a target for the treatment of cognitive dysfunction in patients with Alzheimer's disease (AD). Abnormalities in GRPR-triggered signaling have been described in both fibroblasts from patients with AD, and in transgenic mouse models of AD. Pharmacological and genetic preclinical studies have indicated that BLPs and the GRPR are importantly involved in regulating cognitive function. Moreover, drugs acting at the GRPR have been shown to enhance memory and ameliorate cognitive dysfunction in experimental models of amnesia associated with AD. Taken together, these findings support the view that the GRPR is a novel therapeutic target for the treatment of memory deficits associated with AD.
id ANCC-1_73aa7c97eb7f215f4af324592f309d50
oai_identifier_str oai:scielo:S1980-57642007000200118
network_acronym_str ANCC-1
network_name_str Dementia & Neuropsychologia
repository_id_str
spelling Targeting the gastrin-releasing peptide receptor pathway to treat cognitive dysfunction associated with Alzheimer's Diseasebombesin-like peptidesgastrin-releasing peptidegastrin-releasing peptide receptorcognitive enhancersmemory disordersAlzheimer disease.Abstract Increasing evidence indicates that bombesin (BB)-like peptides (BLPs), such as the gastrin-releasing peptide (GRP) and its receptor (GRPR), might play a role in neurological and psychiatric disorders. The present study reviews findings from animal and human studies suggesting that the GRPR should be considered a target for the treatment of cognitive dysfunction in patients with Alzheimer's disease (AD). Abnormalities in GRPR-triggered signaling have been described in both fibroblasts from patients with AD, and in transgenic mouse models of AD. Pharmacological and genetic preclinical studies have indicated that BLPs and the GRPR are importantly involved in regulating cognitive function. Moreover, drugs acting at the GRPR have been shown to enhance memory and ameliorate cognitive dysfunction in experimental models of amnesia associated with AD. Taken together, these findings support the view that the GRPR is a novel therapeutic target for the treatment of memory deficits associated with AD.Academia Brasileira de Neurologia, Departamento de Neurologia Cognitiva e Envelhecimento2007-06-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1980-57642007000200118Dementia & Neuropsychologia v.1 n.2 2007reponame:Dementia & Neuropsychologiainstname:Associação de Neurologia Cognitiva e do Comportamento (ANCC)instacron:ANCC10.1590/s1980-57642008dn10200002info:eu-repo/semantics/openAccessRoesler,RafaelLuft,TatianaSchwartsmann,Gilbertoeng2017-06-07T00:00:00Zoai:scielo:S1980-57642007000200118Revistahttp://www.demneuropsy.com.br/ONGhttps://old.scielo.br/oai/scielo-oai.php||demneuropsy@uol.com.br1980-57641980-5764opendoar:2017-06-07T00:00Dementia & Neuropsychologia - Associação de Neurologia Cognitiva e do Comportamento (ANCC)false
dc.title.none.fl_str_mv Targeting the gastrin-releasing peptide receptor pathway to treat cognitive dysfunction associated with Alzheimer's Disease
title Targeting the gastrin-releasing peptide receptor pathway to treat cognitive dysfunction associated with Alzheimer's Disease
spellingShingle Targeting the gastrin-releasing peptide receptor pathway to treat cognitive dysfunction associated with Alzheimer's Disease
Roesler,Rafael
bombesin-like peptides
gastrin-releasing peptide
gastrin-releasing peptide receptor
cognitive enhancers
memory disorders
Alzheimer disease.
title_short Targeting the gastrin-releasing peptide receptor pathway to treat cognitive dysfunction associated with Alzheimer's Disease
title_full Targeting the gastrin-releasing peptide receptor pathway to treat cognitive dysfunction associated with Alzheimer's Disease
title_fullStr Targeting the gastrin-releasing peptide receptor pathway to treat cognitive dysfunction associated with Alzheimer's Disease
title_full_unstemmed Targeting the gastrin-releasing peptide receptor pathway to treat cognitive dysfunction associated with Alzheimer's Disease
title_sort Targeting the gastrin-releasing peptide receptor pathway to treat cognitive dysfunction associated with Alzheimer's Disease
author Roesler,Rafael
author_facet Roesler,Rafael
Luft,Tatiana
Schwartsmann,Gilberto
author_role author
author2 Luft,Tatiana
Schwartsmann,Gilberto
author2_role author
author
dc.contributor.author.fl_str_mv Roesler,Rafael
Luft,Tatiana
Schwartsmann,Gilberto
dc.subject.por.fl_str_mv bombesin-like peptides
gastrin-releasing peptide
gastrin-releasing peptide receptor
cognitive enhancers
memory disorders
Alzheimer disease.
topic bombesin-like peptides
gastrin-releasing peptide
gastrin-releasing peptide receptor
cognitive enhancers
memory disorders
Alzheimer disease.
description Abstract Increasing evidence indicates that bombesin (BB)-like peptides (BLPs), such as the gastrin-releasing peptide (GRP) and its receptor (GRPR), might play a role in neurological and psychiatric disorders. The present study reviews findings from animal and human studies suggesting that the GRPR should be considered a target for the treatment of cognitive dysfunction in patients with Alzheimer's disease (AD). Abnormalities in GRPR-triggered signaling have been described in both fibroblasts from patients with AD, and in transgenic mouse models of AD. Pharmacological and genetic preclinical studies have indicated that BLPs and the GRPR are importantly involved in regulating cognitive function. Moreover, drugs acting at the GRPR have been shown to enhance memory and ameliorate cognitive dysfunction in experimental models of amnesia associated with AD. Taken together, these findings support the view that the GRPR is a novel therapeutic target for the treatment of memory deficits associated with AD.
publishDate 2007
dc.date.none.fl_str_mv 2007-06-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1980-57642007000200118
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1980-57642007000200118
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/s1980-57642008dn10200002
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Academia Brasileira de Neurologia, Departamento de Neurologia Cognitiva e Envelhecimento
publisher.none.fl_str_mv Academia Brasileira de Neurologia, Departamento de Neurologia Cognitiva e Envelhecimento
dc.source.none.fl_str_mv Dementia & Neuropsychologia v.1 n.2 2007
reponame:Dementia & Neuropsychologia
instname:Associação de Neurologia Cognitiva e do Comportamento (ANCC)
instacron:ANCC
instname_str Associação de Neurologia Cognitiva e do Comportamento (ANCC)
instacron_str ANCC
institution ANCC
reponame_str Dementia & Neuropsychologia
collection Dementia & Neuropsychologia
repository.name.fl_str_mv Dementia & Neuropsychologia - Associação de Neurologia Cognitiva e do Comportamento (ANCC)
repository.mail.fl_str_mv ||demneuropsy@uol.com.br
_version_ 1754212929175027712

Registros relacionados